KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics, Inc. (PVLA) Non-Current Deffered Revenue (2016 - 2022)

Palvella Therapeutics (PVLA) has disclosed Non-Current Deffered Revenue for 8 consecutive years, with $759000.0 as the latest value for Q2 2023.

  • On a quarterly basis, Non-Current Deffered Revenue changed N/A to $759000.0 in Q2 2023 year-over-year; TTM through Jun 2023 was $759000.0, a N/A change, with the full-year FY2022 number at $18.7 million, down 51.22% from a year prior.
  • Non-Current Deffered Revenue was $759000.0 for Q2 2023 at Palvella Therapeutics, down from $11.7 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $58.1 million in Q2 2019 to a low of $759000.0 in Q2 2023.
  • A 5-year average of $33.4 million and a median of $36.9 million in 2020 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: soared 30.59% in 2021, then plummeted 61.95% in 2023.
  • Palvella Therapeutics' Non-Current Deffered Revenue stood at $47.3 million in 2019, then dropped by 24.03% to $35.9 million in 2020, then grew by 6.97% to $38.4 million in 2021, then tumbled by 51.22% to $18.7 million in 2022, then tumbled by 95.95% to $759000.0 in 2023.
  • Per Business Quant, the three most recent readings for PVLA's Non-Current Deffered Revenue are $759000.0 (Q2 2023), $11.7 million (Q1 2023), and $18.7 million (Q4 2022).